PDCD1 and small cell lung carcinoma: The clinical development of immunotherapy, especially anti-programmed cell death protein 1/programmed cell death 1 ligand 1 (PD-1/PD-L1) therapy, has been a revolutionary milestone in the treatment landscape of ES-SCLC in recent years.